Asset Details
Do you wish to reserve the book?
Management of ischemic optic neuropathies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Management of ischemic optic neuropathies
Do you wish to request the book?
Management of ischemic optic neuropathies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Management of ischemic optic neuropathies
2011
Overview
Ischemic optic neuropathies (IONs) consist primarily of two types: anterior ischemic optic neuropathy (AION) and posterior ischemic optic neuropathy (PION). AION comprises arteritic AION (A-AION: due to giant cell arteritis) and non-arteritic AION (NA-AION: due to other causes). PION consists of arteritic PION (A-PION: due to giant cell arteritis), non-arteritic PION (NA-PION: due to other causes), and surgical PION (a complication of several systemic surgical procedures). These five types of ION are distinct clinical entities etiologically, pathogenetically, clinically and from the management point of view. In the management of AION, the first crucial step with patients aged 50 and over is to identify immediately whether it is arteritic or not because A-AION is an ophthalmic emergency and requires urgent treatment with high-dose steroid therapy to prevent any further visual loss in one or both eyes. Patients with NA-AION, when treated with systemic corticosteroid therapy within first 2 weeks of onset, had significantly better visual outcome than untreated ones. Systemic risk factors, particularly nocturnal arterial hypotension, play major roles in the development of NA-AION; management of them is essential in its prevention and management. NA-PION patients, when treated with high-dose systemic steroid therapy during the very early stages of the disease, showed significant improvement in visual acuity and visual fields, compared to untreated eyes. A-PION, like A-AION, requires urgent treatment with high-dose steroid therapy to prevent any further visual loss in one or both eyes. There is no satisfactory treatment for surgical PION, except to take prophylactic measures to prevent its development.
Publisher
Medknow Publications and Media Pvt. Ltd,Medknow Publications & Media Pvt. Ltd,Medknow Publications,Wolters Kluwer Medknow Publications
Subject
/ Anterior ischemic optic neuropathy
/ arteritic anterior ischemic optic neuropathy
/ Dose-Response Relationship, Drug
/ Giant Cell Arteritis - complications
/ Glaucoma
/ Humans
/ Ions
/ Ischemia
/ non-arteritic anterior ischemic optic neuropathy
/ non-arteritic posterior ischemic optic neuropathy
/ Optic Neuropathy, Ischemic - classification
/ Optic Neuropathy, Ischemic - complications
/ Optic Neuropathy, Ischemic - drug therapy
/ Optic Neuropathy, Ischemic - etiology
/ posterior ischemic optic neuropathy
/ Steroids - administration & dosage
/ Vision Disorders - physiopathology
